Efficacy and safety of concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced nasopharyngeal cancers

Basit Öğe Kaydı
dc.contributor.authorBaykara, Meltem
dc.contributor.authorBuyukberber, Suleyman
dc.contributor.authorOzturk, Banu
dc.contributor.authorCoskun, Ugur
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorUnsal, Diclehan Kilic
dc.contributor.authorDane, Faysal
dc.date.accessioned2024-04-24T17:14:34Z
dc.date.available2024-04-24T17:14:34Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractAims and background. Chemoradiation using cisplatin-based regimens has become the standard care in the treatment of nasopharyngeal cancers, The impact of taxanes as radiosensitizing agents with concurrent chemoradiation regimens is unknown. We retrospectively evaluated the efficacy and tolerability of weekly cisplatin + docetaxel combination with chemoradiation in locally advanced nasopharyngeal cancers. Methods. Forty-two patients with locally advanced nasopharyngeal cancers (59.5% stage IV, 23.3% stage III, and 16.7% stage II) were assessed retrospectively. Total radiation dose to the planning target volume of gross disease (primary and/or node) was 70 Gy/35 fractions, 5 fractions per week. Minimum doses of 60 Gy and 50 Gy were administered to planning target volume of elective high-risk and low-risk disease, respectively. Chemotherapy consisted of weekly cisplatin (20 mg/m(2)) + docetaxel (20 mg/m2) concurrently with radiotherapy. Results. The median age of the patients was 46.5 years (range, 17-79). Objective response rate was 86%. The 4-year progression-free survival and overall survival were 65.4% and 91.3%, respectively. The most common grade 3 and 4 toxicities were mucositis (48%), nausea (22%), neutropenia (12%), dermatitis (5%), fatigue (5%) and weight loss (5%). Conclusions. Weekly cisplatin and docetaxel concurrent with radiotherapy for locally advanced nasopharyngeal cancers was found tolerable with a high efficacy.en_US
dc.identifier.doi10.1177/030089161309900405
dc.identifier.endpage473en_US
dc.identifier.issn0300-8916
dc.identifier.issn2038-2529
dc.identifier.issue4en_US
dc.identifier.pmid24326834
dc.identifier.scopus2-s2.0-84890880834
dc.identifier.scopusqualityQ3
dc.identifier.startpage469en_US
dc.identifier.urihttps://doi.org/10.1177/030089161309900405
dc.identifier.urihttps://hdl.handle.net/11468/18069
dc.identifier.volume99en_US
dc.identifier.wosWOS:000329001000005
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherPensiero Scientifico Editoren_US
dc.relation.ispartofTumori
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChemoradiotherapyen_US
dc.subjectCisplatinen_US
dc.subjectDocetaxelen_US
dc.subjectNasopharyngeal Canceren_US
dc.titleEfficacy and safety of concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced nasopharyngeal cancersen_US
dc.titleEfficacy and safety of concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced nasopharyngeal cancers
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu